H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Aravive (ARAV – Research Report) today and set a price target of $26.00. The company’s shares closed last Thursday at $4.85, close to its 52-week low of $3.34.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 24.4% and a 52.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Catabasis Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aravive with a $26.00 average price target.
The company has a one-year high of $15.62 and a one-year low of $3.34. Currently, Aravive has an average volume of 169.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aravive, Inc. is a clinical-stage biotechnology company, which engages in developing new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments, and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.